Health Evidence Network synthesis report 53
World's largest Science, Technology & Medicine Open Access book publisher
Chapter 7 from the book People's Movements in the 21st Century - Risks, Challenges and Benefits
Trials (2017) 18:152, DOI 10.1186/s13063-017-1881-z
Int J Health Policy Manag 2017, 6(10), 587–600
Low-income countries face many contextual challenges to manage healthcare technologies effectively, as the majority are imported and resources are constrained to a greater extent. Previous healthcare technology management (HTM) policies in Benin ha...ve failed to produce better quality of care for the population and cost-effectiveness for the government. This study aims to identify and assess the main problems facing HTM in Benin’s public health sector, as well as the ability of key actors within the sector to address these problems.
more
The Community Action Research on Disability (CARD) programme in Uganda embraced and modified the EDR approach, recognising the need for including people with disability in the research process from concept to outcome, and nurturing participation and collaboration between all the stakeholders in achi...eving action-based research. T
more
Guidance
Second Edition
Monitoring and Evaluation
Key Populations Brief
Accessed November 2017
Tackling Tuberculosis in Under-Served Populations: A Resource for TB Control Boards and their partners
UNAIDS 2017 / Reference
Generating evidence for policy and action on HIV and social protection
РУКОВОДСТВО ДЛЯ АКТИВИСТОВ ПО ИНСТРУМЕНТАМ ДЛЯ ДИАГНОСТИКИ ТУБЕРКУЛЕЗА ЯНВАРЬ.
5th revised edition.
This document provides a ranking of medically important antimicrobials for risk management of antimicrobial resistance due to non-human use. The current revision took place at the seventh meeting of the AGISAR held in Raleigh, United States of America in 2016.
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more